Nandrolone Decanoate (Decadurabolin)

Decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat WASTING SYNDROME associated with severe chronic illness or HIV infection (HIV WASTING SYNDROME). It may also be used in the treatment of POSTMENOPAUSAL OSTEOPOROSIS.

Also Known As:

Decadurabolin; 17 beta-Hydroxyestr-4-en-3-one 17-decanoate; 19-Nortestosterone Decanoate; 19-nor-4-Androstene-17 beta-ol-3-one 17-decanoate; Decadurobolin; Retabolil; Retabolyl; 17 beta Hydroxyestr 4 en 3 one 17 decanoate; 19 Nortestosterone Decanoate; 19 nor 4 Androstene 17 beta ol 3 one 17 decanoate

Networked: 203 relevant articles (11 outcomes, 35 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Camargo, Isabel Cristina Cherici: 3 articles (04/2014 - 07/2005)
2.	Bissoli, Nazaré Souza: 3 articles (03/2013 - 06/2009)
3.	Fortunato, Rodrigo Soares: 2 articles (10/2020 - 06/2006)
4.	de Carvalho, Denise Pires: 2 articles (10/2020 - 06/2006)
5.	Chuffa, L G A: 2 articles (01/2016 - 09/2009)
6.	Ahmed, Maha A E: 2 articles (07/2015 - 02/2015)
7.	Costa, Waldemar Silva: 2 articles (07/2015 - 09/2013)
8.	Souza, Diogo Benchimol de: 2 articles (07/2015 - 09/2013)
9.	de Andrade, Tadeu Uggere: 2 articles (03/2013 - 06/2009)
10.	Medeiros, Ana Raquel Santos: 2 articles (12/2011 - 06/2009)

Related Diseases

1.	HIV Infections (HIV Infection) 06/01/1996 - "Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection." 05/01/2009 - "Recent studies have demonstrated the role of nandrolone decanoate (ND) in reversal of wasting associated with HIV infection. " 03/14/2005 - "Nandrolone decanoate therapy may prove to be generally safe and beneficial in reversing weight loss and lean tissue loss in women with HIV infection and other chronic catabolic diseases." 09/01/1996 - "A randomized study of nandrolone decanoate (Deca-Durabolin) showed that the anabolic steroid can increase weight in people with HIV infections. "
2.	Anemia 01/01/2005 - "Our target is to assess the safety and the efficacy of nandrolone decanoate (ND) as an effective adjunctive therapy to treat such anemia. " 01/01/1999 - "To assess the efficiency of nandrolone decanoate (ND) in the control of anemia in elderly male patients on hemodialysis (HD), and to determine its influence on nutritional parameters. " 01/01/1999 - "Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis." 11/01/1988 - "Nandrolone decanoate therapy for anemia in patients on haemodialysis." 04/01/1983 - "Symptomatic palliation of the severe anemia was attained in this patient by injections of nandrolone decanoate. "
3.	Weight Loss (Weight Reduction) 07/01/1986 - "There was a trend for less severe weight loss on the nandrolone decanoate arm (average weight loss 0.8 +/- 0.15 kg versus 0.21 +/- 0.18 kg, respectively), with half as many patients experiencing weight loss on nandrolone decanoate (25% versus 12%). " 03/14/2005 - "In this randomized, double-blind, placebo-controlled, multicenter, phase I/II study, 38 HIV-infected women with documented weight loss of 5% or greater in the preceding year or a body mass index of less than 20 kg/m(2) were randomized to receive nandrolone decanoate (100 mg) or an equivalent volume of placebo every other week by intramuscular injection. " 03/14/2005 - "Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial." 02/01/1999 - "Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss." 07/01/1986 - "Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer."
4.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2008 - "Sixteen patients with severe COPD were randomized to either placebo or nandrolone decanoate. " 10/01/1995 - "Two hundred seventeen patients with COPD participated in a placebo-controlled, randomized trial investigating the physiologic effects of nutritional intervention alone (N) for 8 wk or combined with the anabolic steroid nandrolone decanoate (N + A). " 01/01/2008 - "Administration of anabolic steroids (nandrolone decanoate) outside a dedicated rehabilitation program did not lead to either weight gain, improvement in physiological function, or better quality of life in patients with severe COPD." 11/01/2003 - "We randomly assigned 63 male patients with COPD to receive on days 1, 15, 29, and 43 a deep IM injection of 50 mg of nandrolone decanoate (ND) [Deca-Durabolin; N.V. Organon; Oss, The Netherlands] in 1 mL of arachis oil, or 1 mL of arachis oil alone (placebo) in a double-blind design. "
5.	Chronic Kidney Failure (Chronic Renal Failure) 10/01/1997 - "We conclude that the combination of low-dose rHuEPO and nandrolone decanoate is effective treatment for the anemia of end-stage renal failure." 04/01/2001 - "The role of nandrolone decanoate in patients with end stage renal disease in the erythropoietin era." 01/01/1978 - "A double blind cross-over trial of Nandrolone decanoate (Decadurabolin) was carried out in 27 patients with anaemia due to end stage renal disease, stabilised on regular haemodialysis. "

Related Drugs and Biologics

1.	Anabolic Androgenic Steroids
2.	alvesin
3.	Methylprednisolone
4.	Calcium
5.	Testosterone (Sustanon)
6.	Nandrolone Decanoate (Decadurabolin)
7.	Tamoxifen
8.	Proteins (Proteins, Gene)
9.	Erythropoietin
10.	nandrolone phenpropionate (Durabolin)

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Intramuscular Injections
4.	Renal Dialysis (Hemodialysis)
5.	Hormone Replacement Therapy (Therapy, Hormone Replacement)